pharma · Obesity · Type 2 diabetes
NovoThirteen
NovoThirteen is a pharma organization headquartered in Bagsværd, JP. Primary therapeutic focus areas include Obesity, Type 2 diabetes, Type 2 Diabetes, Mild cognitive impairment (MCI) or mild dementia, both of the Alzhei
Company details
- Status
- Public
- HQ
- Bagsværd, JP
- Programs
- 94
- Drugs
- 67
- Patents
- 0
NN7442-8454
Phase 1 · other · Haemophilia A with or without inhibitors. Proposed indication under development: prevention of bleeding and long-term prophylaxis in patients with haemophilia A, irrespective of inhibitor status or severity.
NN7442-8454 for Haemophilia A with or without inhibitors. Proposed indication under development: prevention of bleeding and long-term prophylaxis in patients with haemophilia A, irrespective of inhibitor status or severity. is a Phase 1 program (other) at NovoThirteen with 1 ClinicalTrials.gov record(s).
Internal code NN7442-8454
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- NovoThirteen
- Phase
- Phase 1
- Modality
- other
- Indication
- Haemophilia A with or without inhibitors. Proposed indication under development: prevention of bleeding and long-term prophylaxis in patients with haemophilia A, irrespective of inhibitor status or severity.
- Status
- active
- Trials
- 1